Abstract Background The bone marrow (BM) niche contains non-hematopoietic elements including mesenchymal stromal cells (MSC) and bone marrow endothelial cells (BMEC) which provide mechanical support, and control hematopoietic cell growth and differentiation. Although it is known that multiple myeloma (MM) cells interact closely with the BM microenvironment, little is known about the impact of MM on non-hematopoietic niche-forming cells. Methods To address the role of the niche in MM pathogenesis, we utilized the 5…

Abstract Functional high-risk (FHR) multiple myeloma (MM) is defined as an unexpected, early relapse (ER) of disease in the absence of baseline molecular or clinical risk factors (RF), making FHR MM inherently dependent on which RFs were assessed at diagnosis, and what treatment patients received. To establish the true incidence of FHR, we analyzed uniformly treated, transplant-eligible patients from the Myeloma-XI (MyXI) trial that had been profiled for the International Myeloma Society and Working Group (IMS/IMW…

<p>Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 p…

<p>Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 p…

<p>Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID8-associated Peaks in ID8-negative Cases. Figure S5: Indel profiles of select ID8-positive subgroups. Figure S6: Similarity of ID8 Regardless of Disease Histology. Figure S7: Genomic Complexity has No Bearing on ID8 Contribution. Figure S8: De novo SBS96 and ID83 extract…